Noteworthy, ketoconazole was also found to inhibit ACTH release in both in vitro studies on AtT20 mouse corticotroph tumor cell line and on human corticotroph tumor cell cultures and in vivo in rats, thus potentially suggesting a double pharmacodynamic action of potential use in CD patients (4). Here, POMC is linked to neoplasm.